Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES LLOYD WADE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1992774459
CMS profile
44908
Location
DECATUR, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,806.73

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,806.73 144

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES LLOYD WADE

NPI 1992774459 · CMS profile ID 44908

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DECATUR, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992774459?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992774459?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992774459?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JAMES LLOYD WADE, NPI 1992774459, CMS profile ID 44908, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1992774459?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $2,806.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $38.3904/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885860853 CMS
Novartis Pharmaceuticals Corporation $12.0504/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438479 CMS
Lilly USA, LLC $13.4703/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918027761 CMS
EISAI INC. $15.6403/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908044121 CMS
Pharmacyclics LLC, an AbbVie Company $28.5903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890349447 CMS
GENZYME CORPORATION $22.7103/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938744175 CMS
AstraZeneca Pharmaceuticals LP $17.9003/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914998359 CMS
Novartis Pharmaceuticals Corporation $13.0903/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438477 CMS
Pharmacyclics LLC, an AbbVie Company $18.1703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890349445 CMS
Janssen Biotech, Inc. $24.7703/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885860823 CMS
GENZYME CORPORATION $16.8103/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938744153 CMS
Janssen Biotech, Inc. $16.1403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885860847 CMS
Novartis Pharmaceuticals Corporation $16.5003/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438469 CMS
Novartis Pharmaceuticals Corporation $20.4103/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438467 CMS
Janssen Biotech, Inc. $20.8303/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885860889 CMS
Lilly USA, LLC $17.6403/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918045675 CMS
Pharmacyclics LLC, an AbbVie Company $17.7003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890349443 CMS
AstraZeneca Pharmaceuticals LP $14.6702/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915790605 CMS
Novartis Pharmaceuticals Corporation $13.4702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438465 CMS
Novartis Pharmaceuticals Corporation $10.5002/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438471 CMS
AstraZeneca Pharmaceuticals LP $17.5002/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915481039 CMS
Novartis Pharmaceuticals Corporation $16.7002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438475 CMS
Novartis Pharmaceuticals Corporation $15.2102/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438473 CMS
Genentech USA, Inc. $4.6502/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950800293 CMS
Genentech USA, Inc. $9.8402/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950800295 CMS
ABBVIE INC. $29.6402/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892600697 CMS
Amgen Inc. $16.7002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939210415 CMS
GENZYME CORPORATION $12.0602/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938744141 CMS
AstraZeneca Pharmaceuticals LP $16.5002/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915055205 CMS
Seagen Inc. $13.9901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904108625 CMS
EISAI INC. $17.5001/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908044107 CMS
Pharmacyclics LLC, an AbbVie Company $15.5201/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890349441 CMS
Merck Sharp & Dohme LLC $15.8101/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086701 CMS
Pharmacyclics LLC, an AbbVie Company $19.5901/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890349439 CMS
Alexion Pharmaceuticals, Inc. $19.0801/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914829037 CMS
Lilly USA, LLC $17.6201/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918080787 CMS
AstraZeneca Pharmaceuticals LP $20.2701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914754393 CMS
EISAI INC. $15.1001/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908044125 CMS
Merck Sharp & Dohme LLC $14.2701/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944063841 CMS
Mylan Institutional Inc. $17.3101/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963952499 CMS
ADC Therapeutics America, Inc. $14.4201/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060940031 CMS
Adaptive Biotechnologies Corporation $15.6501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951437163 CMS
Novartis Pharmaceuticals Corporation $11.3401/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894438463 CMS
SERVIER PHARMACEUTICALS LLC $17.6701/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964204313 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,714.85 145
PY2020 $948.06 42
PY2021 $1,370.71 88
PY2022 $2,806.73 144
PY2023 $4,185.31 134
PY2024 $7,785.35 100
PY2025 $291.59 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $508,074.52 87
PY2024 Principal investigator $70,508.04 33
PY2023 Principal investigator $448,790.19 58
PY2022 Principal investigator $264,960.61 54
PY2021 Principal investigator $496,920.45 39
PY2020 Principal investigator $251,088.15 56
PY2019 Recipient $26.40 1
PY2019 Principal investigator $621,621.65 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $7,968.73 12/27/2025 Non-covered Recipient Entity
CANCER CARE SPECIALISTS OF ILLINOIS
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228732141
Principal investigator 1 Janssen Research & Development, LLC $4,296.00 12/26/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175428596
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/22/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175428734
Principal investigator 1 BioNTech SE $688.50 12/19/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249013073
Principal investigator 1 PFIZER INC. $46,207.89 12/11/2025 Non-covered Recipient Entity
Cancer Care Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228714122
Principal investigator 1 BioNTech SE $688.50 12/04/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249013069
Principal investigator 1 BioNTech SE $15.60 12/01/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT122 No dispute reported 06/30/2026 1249013079
Principal investigator 1 PFIZER INC. $520.00 11/24/2025 Covered Recipient Teaching Hospital
DECATUR MEMORIAL HOSPITAL
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228727445
Principal investigator 1 BioNTech SE $1,377.00 11/20/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249013085
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 11/20/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298920
Principal investigator 1 PFIZER INC. $10,687.02 11/14/2025 Non-covered Recipient Entity
CANCER CARE SPECIALISTS OF ILLINOIS
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228729243
Principal investigator 1 BeOne Medicines USA, Inc. $750.00 11/12/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329223
Principal investigator 1 Janssen Research & Development, LLC $11,334.00 11/07/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175428193
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,618.00 11/05/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lung04 No dispute reported 06/30/2026 1185543352
Principal investigator 1 PFIZER INC. $1,750.00 11/04/2025 Non-covered Recipient Entity
Exigent Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228729494
Principal investigator 1 Daiichi Sankyo Inc. $51.75 11/03/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois
DS1062-328 No dispute reported 06/30/2026 1223365273
Principal investigator 1 Daiichi Sankyo Inc. $94.00 11/03/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois
DS1062-328 No dispute reported 06/30/2026 1223365275
Principal investigator 1 Daiichi Sankyo Inc. $376.00 11/03/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois
DS1062-328 No dispute reported 06/30/2026 1223365277
Principal investigator 1 BioNTech SE $15.60 11/01/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT122 No dispute reported 06/30/2026 1249013077
Principal investigator 1 BioNTech SE $688.50 10/09/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249013071
Principal investigator 1 PFIZER INC. $520.00 10/06/2025 Covered Recipient Teaching Hospital
DECATUR MEMORIAL HOSPITAL
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228722662
Principal investigator 1 BioNTech SE $15.60 10/01/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT122 No dispute reported 06/30/2026 1249013075
Principal investigator 1 PFIZER INC. $67,584.75 09/29/2025 Non-covered Recipient Entity
UNIVERSITY OF LOUISIANA ATLAFAYETTE
Not supplied No dispute reported 06/30/2026 1228758299
Principal investigator 1 AstraZeneca Pharmaceuticals LP $900.00 09/19/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185543354
Principal investigator 1 PFIZER INC. $27,036.00 09/09/2025 Non-covered Recipient Entity
Exigent Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228770785
Principal investigator 1 BioNTech SE $15.60 09/01/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur
BNT122-01 No dispute reported 06/30/2026 1249017352
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,086.28 08/20/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185543350
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,450.00 08/14/2025 Covered Recipient Teaching Hospital
Springfield Memorial Hospital
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1236000248
Principal investigator 1 BeOne Medicines USA, Inc. $3,150.00 08/12/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329219
Principal investigator 1 BioNTech SE $15.60 08/01/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur
BNT122-01 No dispute reported 06/30/2026 1249017350
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298422
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298521
Principal investigator 1 Janssen Research & Development, LLC $426.40 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298538
Principal investigator 1 Janssen Research & Development, LLC $426.40 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298743
Principal investigator 1 Janssen Research & Development, LLC $426.40 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298819
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298881
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298999
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299031
Principal investigator 1 Janssen Research & Development, LLC $426.40 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299111
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299171
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299250
Principal investigator 1 Janssen Research & Development, LLC $750.88 08/01/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299393
Principal investigator 1 BeOne Medicines USA, Inc. $750.00 07/15/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329221
Principal investigator 1 BioNTech SE $15.60 07/01/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur
BNT122-01 No dispute reported 06/30/2026 1249017348
Principal investigator 1 BioNTech SE $925.00 06/24/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012915
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,460.25 06/24/2025 Non-covered Recipient Entity
Decatur Memorial Hospital
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1235997748
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,460.02 06/24/2025 Non-covered Recipient Entity
Cancer Care Specialists Of Illinois
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1235998432
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 06/23/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298901
Principal investigator 1 BioNTech SE $600.00 06/19/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT-122-01 No dispute reported 06/30/2026 1249012917
Principal investigator 1 BioNTech SE $1,377.00 06/12/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012925
Principal investigator 1 Celgene Corporation $22,000.00 06/04/2025 Non-covered Recipient Entity
Exigent Research Llc
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222307011
Principal investigator 1 Janssen Research & Development, LLC $274.00 06/04/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298945
Principal investigator 1 AstraZeneca Pharmaceuticals LP $124,870.42 05/30/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185543346
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298370
Principal investigator 1 Janssen Research & Development, LLC $426.40 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298392
Principal investigator 1 Janssen Research & Development, LLC $750.88 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298639
Principal investigator 1 Janssen Research & Development, LLC $750.88 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298717
Principal investigator 1 Janssen Research & Development, LLC $426.40 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299356
Principal investigator 1 Janssen Research & Development, LLC $14,000.00 05/27/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175428389
Principal investigator 1 BioNTech SE $688.50 05/15/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012923
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 04/30/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298490
Principal investigator 1 BioNTech SE $1,377.00 04/28/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012921
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298431
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298652
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298667
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298707
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298814
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299006
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299119
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299236
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299286
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299431
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299469
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299540
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299597
Principal investigator 1 BioNTech SE $1,377.00 04/23/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012919
Principal investigator 1 Janssen Research & Development, LLC $32,000.00 04/15/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175428489
Principal investigator 1 PFIZER INC. $520.00 04/14/2025 Covered Recipient Teaching Hospital
DECATUR MEMORIAL HOSPITAL
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228780589
Principal investigator 1 BioNTech SE $1,377.00 03/19/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012913
Principal investigator 1 BioNTech SE $688.50 03/04/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012911
Principal investigator 1 BioNTech SE $688.50 02/25/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012909
Principal investigator 1 PFIZER INC. $520.00 02/03/2025 Covered Recipient Teaching Hospital
DECATUR MEMORIAL HOSPITAL
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228793128
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,336.61 01/29/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185543348
Principal investigator 1 BioNTech SE $688.50 01/21/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012907
Principal investigator 1 BioNTech SE $688.50 01/17/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012905
Principal investigator 1 BioNTech SE $688.50 01/07/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012901
Principal investigator 1 BioNTech SE $1,377.00 01/07/2025 Covered Recipient Teaching Hospital
Decatur Memorial Hospital
BNT000-001 No dispute reported 06/30/2026 1249012903